

---

# Konstruktionsfehler, Myokarditis & Stammzellen

---

Florian Schilling




Research

JAMA Cardiology | **Original Investigation**


## SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Øystein Karlstad, MScPharm, PhD; Petteri Hovi, MD, PhD; Anders Husby, MD, PhD; Tommi Härkänen, PhD; Randi Marie Selmer, MSc, PhD; Nicklas Pihlström, MSc; Jørgen Vinsløv Hansen, MSc, PhD; Hanna Nohynek, MD, PhD; Nina Gunnes, MSc, PhD; Anders Sundström, BA, PhD; Jan Wohlfahrt, MSc, DMSC; Tuomo A. Nieminen, MSocSc; Maria Grunewald, MSc, PhD; Hanne Løvdal Gulseth, MD, PhD; Anders Hviid, MSc, DMSC; Rickard Ljung, MD, PhD, MPH

**IMPORTANCE** Reports of myocarditis after SARS-CoV-2 messenger RNA (mRNA) vaccination have emerged.

 [Editor's Note page 612](#)

 [Supplemental content](#)





## Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study

*Ian Kracalik, Matthew E Oster, Karen R Broder, Margaret M Cortese, Maleeka Glover, Karen Shields, C Buddy Creech, Brittney Romanson, Shannon Novosad, Jonathan Soslow, Emmanuel B Walter, Paige Marquez, Jeffrey M Dendy, Jared Woo, Amy L Valderrama, Alejandra Ramirez-Cardenas, Agape Assefa, M Jay Campbell, John R Su, Shelley S Magill, David K Shay, Tom T Shimabukuro, Sridhar V Basavaraju, for the Myocarditis Outcomes After mRNA COVID-19 Vaccination Investigators and the CDC COVID-19 Response Team*

- ▶ 519 Myokarditis-Fälle nach Impfung, Median 17 Jahre
- ▶ nach 90 Tagen 81 % „considered fully recovered“
- ▶ 68% „cleared for all physical activity“
- ▶ Follow-Up-MRI:
  - ▶ 54% mit „Auffälligkeiten“
  - ▶ 13% mit persistierender Myokarditis



## The Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients—A Large Population-Based Study

by  Ortal Tuvali <sup>1,†</sup>  Sagi Tshori <sup>2,†</sup>  Estela Derazne <sup>3</sup>  Rebecca Regina Hannuna <sup>2</sup>  Arnon Afek <sup>3,4</sup>  Dan Haberman <sup>1</sup>  Gal Sella <sup>1</sup> and  Jacob George <sup>1,\*</sup>    

<sup>1</sup> Heart Center, Kaplan Medical Center, Rehovot, Hebrew University of Jerusalem, Jerusalem 91905, Israel

<sup>2</sup> Research Authority, Rehovot, Hebrew University of Jerusalem, Jerusalem 91905, Israel

<sup>3</sup> Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel

<sup>4</sup> General Management, The Chaim Sheba Medical Centre, Tel Hashomer, Ramat-Gan 52621, Israel

\* Author to whom correspondence should be addressed.

† These authors contributed equally to this work.

Academic Editor: Andrea Frustaci

*J. Clin. Med.* **2022**, *11*(8), 2219; <https://doi.org/10.3390/jcm11082219>

Received: 25 March 2022 / Revised: 11 April 2022 / Accepted: 12 April 2022 / Published: 15 April 2022

- ▶ We aimed to study the incidence of post-acute COVID-19 myocarditis and pericarditis.
- ▶ Retrospective cohort study of 196,992 adults after COVID-19 infection ... between March 2020 and January 2021.
- ▶ from day 10 after positive PCR. Follow-up was censored on 28 February 2021, with minimum observation of 18 days.
- ▶ We did not observe an increased incidence of neither pericarditis nor myocarditis in adult patients recovering from COVID-19 infection

## Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents

by Suyanee Mansanguan <sup>1</sup>, Prakaykaew Charunwatthana <sup>2</sup>, Watcharapong Piyaphanee <sup>2</sup>, Wilanee Dechkhajorn <sup>3</sup>, Akkapon Poolcharoen <sup>4</sup> and Chayasiri Mansanguan <sup>2,\*</sup>

<sup>1</sup> Bhumibol Adulyadej Hospital, Bangkok 10220, Thailand

<sup>2</sup> Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

<sup>3</sup> Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

<sup>4</sup> Samitivej Srinakarin Hospital, Bangkok 10250, Thailand

\* Author to whom correspondence should be addressed.

Academic Editor: John Frea


*Trop. Med. Infect. Dis.* **2022**, *7*(8), 196; <https://doi.org/10.3390/tropicalmed7080196>

Received: 21 July 2022 / Revised: 14 August 2022 / Accepted: 17 August 2022 / Published: 19 August 2022

7/301

= 2.3%

1:44



# iScience





Available online 11 November 2022, 105544




In Press, Journal Pre-proof 

Article

## Skewed Fate and Hematopoiesis of CD34+ HSPCs in Umbilical Cord Blood Amid the COVID-19 Pandemic

Benjamin K. Estep<sup>1</sup>, Charles J. Kuhlmann<sup>1</sup>, Satoru Osuka<sup>4</sup>, Gajendra W. Suryavanshi<sup>5</sup>, Yoshiko Nagaoka-Kamata<sup>2</sup>, Ciarria N. Samuel<sup>1</sup>, Madison T. Blucas<sup>1</sup>, Chloe E. Jepson<sup>1</sup>, Paul A. Goepfert<sup>3</sup>, Masakazu Kamata<sup>1</sup>  

**Show more** 

 Add to Mendeley  Share  Cite


<https://doi.org/10.1016/j.isci.2022.105544>

Under a Creative Commons license

[Get rights and content](#)

 [Open access](#)











Kontrolle


Natural infection

Vaccination







**D**



**R<sup>2</sup>=46% (\*\*, p=0.004)**

**R<sup>2</sup>=36% (ns, p=0.1555)**





closed state of SARS-CoV-2 spike protein



- ▶ Mitochondrien-Schädigung
- ▶ Inflammation (Hyper-, Silent-)
- ▶ Hypertonie
- ▶ Gerinnsel
- ▶ Onkogene / DNA-Reparaturgene
- ▶ Abwehrschwäche
- ▶ ...

JOURNAL ARTICLE

## Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

Alana F Ogata, Chi-An Cheng, Michaël Desjardins, Yasmeen Senussi, Amy C Sherman, Megan Powell, Lewis Novack, Salena Von, Xiaofang Li, Lindsey R Baden ... [Show more](#)



[Author Notes](#)

*Clinical Infectious Diseases*, Volume 74, Issue 4, 15 February 2022, Pages 715–718,

<https://doi.org/10.1093/cid/ciab465>

**Published:** 20 May 2021 **Article history** ▼








Furin-Cleavage-Site

S1  
S2








## Circulation

## ORIGINAL RESEARCH ARTICLE


## Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis

Lael M. Yonker<sup>1</sup>, MD<sup>\*</sup>; Zoe Swank, PhD<sup>\*</sup>; Yannic C. Bartsch, PhD<sup>\*</sup>; Madeleine D. Burns<sup>1</sup>, MS; Abigail Kane<sup>1</sup>, MD; Brittany P. Boribong, PhD; Jameson P. Davis, BS; Maggie Loiselle, BS; Tanya Novak<sup>1</sup>, PhD; Yasmeen Senussi<sup>1</sup>, MBBS; Chi-An Cheng<sup>1</sup>, PhD; Eleanor Burgess, MS; Andrea G. Edlow, MD; Janet Chou, MD; Audrey Dionne<sup>1</sup>, MD; Duraisamy Balaguru<sup>1</sup>, MD; Manuella Lahoud-Rahme<sup>1</sup>, MD; Moshe Arditi<sup>1</sup>, PhD; Boris Julg, MD, PhD; Adrienne G. Randolph<sup>1</sup>, MD; Galit Afer, PhD; Alessio Fasano<sup>1</sup>, MD†; David R. Walt<sup>1</sup>, PhD†
















**Cytokine and Chemokine  
Neutralizing Antibodies**  
 $\alpha$ -IL-4 ·  $\alpha$ -IL-17A ·  $\alpha$ -IFN $\gamma$  ·  $\alpha$ -TNF $\alpha$  ·  $\alpha$ -TGF $\beta$

**DISCOVER MORE**



*The Journal of  
Immunology*


RESEARCH ARTICLE | NOVEMBER 15 2021

**Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer–BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines**

**FREE**

Sandhya Bansal; ... et. al  
*J Immunol* (2021) 207 (10): 2405–2410.  
<https://doi.org/10.4049/jimmunol.2100637>

- ▶ 4 Monate Spike bei Geimpften
- ▶ Freies S1 mit aktiver RBD?
- ▶ Anti-ACE2-AAK-Trigger?
- ▶ Falls ja - für wie lange?






In June, *Trial Site News* published a bombshell investigative [report](#) on the leaked European Medicine Agency (EMA) emails and other Pfizer-related confidential reports, which exposed concerning facts in the run-up to the authorization of the Pfizer-BioNTech COVID-19 vaccine. It revealed:

- A politically driven race between key regulators in their rush to authorize the vaccine.
- By late November 2020, regulators including, US FDA, European Medicines Agency, Health Canada and the UK's MHRA, were all aware of the significant loss of RNA integrity of the commercial batches (~55% mRNA integrity) of the Pfizer-BioNTech vaccine compared to the clinical ones (~78% mRNA integrity). This was classified by EMA as a “major objection” along with observed visible particles, which were classified as “impurities.”
- A leaked 26 November PowerPoint presentation of a meeting between Pfizer-BioNTech and the EMA revealed how this major objection was shockingly ‘resolved’- the RNA integrity specification was simply lowered to 50%, therefore half of all mRNA molecules in the commercial batches were allowed to be truncated (not intact).
- The potential implications of the RNA integrity loss in terms of safety and efficacy were unknown.

<https://www.trialsitenews.com/a/a-further-investigation-into-the-leaked-ema-emails-confidential-pfizer-biontech-covid-19-vaccine-related-docs-5102039c>

<https://static1.squarespace.com/static/61910a2d98732d54b73ef8fc/t/633dabb52f698d5970c1ae9c/1664986067060/Pfizer+BioNTech+EU+Agreement+RM++Part2.pdf>





- ▶ Ab sofort erhältlich
- ▶ Deutsch & Englisch
- ▶ Bei [tredition.com](https://tredition.com)
- ▶ Post-Vac & Long-Covid
- ▶ Extrakapitel Vitamin-D
- ▶ Aktualisierte und erweiterte Darstellung